The development of resistance to endocrine therapy is a significant, clinical problem in breast cancer. Here, the authors identify a rare subpopulation of cells that drive resistance following transcriptional reprogramming.
- Sung Pil Hong
- Thalia E. Chan
- Luca Magnani